NZ712691A - C. novyi for the treatment of solid tumors in humans - Google Patents

C. novyi for the treatment of solid tumors in humans

Info

Publication number
NZ712691A
NZ712691A NZ712691A NZ71269114A NZ712691A NZ 712691 A NZ712691 A NZ 712691A NZ 712691 A NZ712691 A NZ 712691A NZ 71269114 A NZ71269114 A NZ 71269114A NZ 712691 A NZ712691 A NZ 712691A
Authority
NZ
New Zealand
Prior art keywords
human
novyi
methods
solid tumor
present
Prior art date
Application number
NZ712691A
Other languages
English (en)
Inventor
Saurabh Saha
Bert Vogelstein
Kenneth W Kinzler
Shibin Zhou
Original Assignee
Biomed Valley Discoveries Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc, Univ Johns Hopkins filed Critical Biomed Valley Discoveries Inc
Publication of NZ712691A publication Critical patent/NZ712691A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
NZ712691A 2013-03-29 2014-03-28 C. novyi for the treatment of solid tumors in humans NZ712691A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806497P 2013-03-29 2013-03-29
PCT/US2014/032196 WO2014160950A1 (en) 2013-03-29 2014-03-28 C. novyi for the treatment of solid tumors in humans

Publications (1)

Publication Number Publication Date
NZ712691A true NZ712691A (en) 2020-01-31

Family

ID=51625539

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712691A NZ712691A (en) 2013-03-29 2014-03-28 C. novyi for the treatment of solid tumors in humans

Country Status (20)

Country Link
US (3) US10617723B2 (enExample)
EP (4) EP2988760B1 (enExample)
JP (7) JP6756609B2 (enExample)
KR (1) KR20160021084A (enExample)
CN (2) CN105451750B (enExample)
AU (2) AU2014240872A1 (enExample)
BR (2) BR122020006408B1 (enExample)
CA (2) CA2908508C (enExample)
DK (1) DK2988760T3 (enExample)
ES (3) ES2815564T3 (enExample)
HK (1) HK1222134A1 (enExample)
IL (1) IL241823B (enExample)
MX (1) MX377118B (enExample)
NZ (1) NZ712691A (enExample)
PH (1) PH12015502260B1 (enExample)
RU (1) RU2718670C2 (enExample)
SG (2) SG10201902765VA (enExample)
UA (1) UA120036C2 (enExample)
WO (1) WO2014160950A1 (enExample)
ZA (2) ZA201507412B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944456C (en) * 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
CN105912930B (zh) * 2016-04-11 2019-02-01 北京奇虎科技有限公司 移动终端及其系统资源安全控制方法
US10815534B2 (en) 2016-08-23 2020-10-27 Mayo Foundation For Medical Education And Research Methods and materials for treating estrogen receptor positive breast cancer
WO2018213302A1 (en) 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
CN109985039A (zh) * 2017-12-29 2019-07-09 深圳微芯生物科技股份有限公司 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途
WO2021231611A1 (en) * 2020-05-12 2021-11-18 Splash Pharmaceuticals, Inc. Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status
US11717787B2 (en) * 2021-01-04 2023-08-08 Saudi Arabian Oil Company High free volume membrane for gas separation
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
CN113855710B (zh) * 2021-10-09 2024-02-20 施慧达药业集团(吉林)有限公司 戈氏梭菌联合肿瘤血管生成抑制剂的应用
CN115350145A (zh) * 2022-09-06 2022-11-18 华中科技大学同济医学院附属协和医院 细菌介导负载二甲双胍的多肽水凝胶在肿瘤免疫治疗中的应用
WO2025163852A1 (ja) * 2024-02-01 2025-08-07 ミヤリサン製薬株式会社 Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
EP0245357B1 (en) 1985-10-23 1991-08-07 The Upjohn Company Angiostatic steroids
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
EP0477195A1 (en) 1989-06-16 1992-04-01 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
AU678961B2 (en) 1991-11-22 1997-06-19 Alcon Laboratories, Inc. Angiostatic steroids
DE60208780T2 (de) 2001-02-28 2006-08-10 Rex Medical, L.P. Vorrichtung zur applikation von ablationsfluid zur behandlung von läsionen
DK1446012T3 (da) * 2001-11-21 2013-10-14 Univ Johns Hopkins Bakteriolytisk kombinationsterapi til behandling af tumorer
WO2005018332A1 (en) 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
EP1675465B1 (en) 2003-10-22 2010-03-03 The Johns Hopkins University Improved combination bacteriolytic therapy for the treatment of tumors
US20070015738A1 (en) * 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid

Also Published As

Publication number Publication date
JP2017088619A (ja) 2017-05-25
SG10201902765VA (en) 2019-04-29
JP2019011376A (ja) 2019-01-24
MX2015013784A (es) 2016-08-08
EP3730146B1 (en) 2022-05-04
DK2988760T3 (da) 2020-07-13
ZA201507412B (en) 2018-05-30
EP4653054A3 (en) 2026-02-25
PH12015502260B1 (en) 2022-11-16
EP4108248B1 (en) 2025-09-17
RU2020111670A (ru) 2020-04-13
KR20160021084A (ko) 2016-02-24
BR112015024621B1 (pt) 2021-09-28
US10617723B2 (en) 2020-04-14
JP7788114B2 (ja) 2025-12-18
CA2908508C (en) 2023-09-19
CN105451750B (zh) 2023-03-10
EP3730146A1 (en) 2020-10-28
SG11201508071VA (en) 2015-10-29
RU2015146199A (ru) 2017-05-10
JP7445893B2 (ja) 2024-03-08
JP2016515586A (ja) 2016-05-30
HK1222134A1 (zh) 2017-06-23
US20160051597A1 (en) 2016-02-25
EP2988760B1 (en) 2020-06-17
US20200330525A1 (en) 2020-10-22
EP4653054A2 (en) 2025-11-26
CA3206655A1 (en) 2014-10-02
JP2022022392A (ja) 2022-02-03
MX377118B (es) 2025-03-07
EP2988760A4 (en) 2016-10-05
AU2014240872A1 (en) 2015-10-22
IL241823B (en) 2021-02-28
CN105451750A (zh) 2016-03-30
PH12015502260A1 (en) 2016-02-01
ZA201706402B (en) 2019-01-30
EP2988760A1 (en) 2016-03-02
JP2026048721A (ja) 2026-03-17
JP2024056012A (ja) 2024-04-19
CA2908508A1 (en) 2014-10-02
AU2019200276B2 (en) 2020-06-11
BR122020006408B1 (pt) 2021-09-28
JP6756609B2 (ja) 2020-09-16
ES3048113T3 (en) 2025-12-09
AU2019200276A1 (en) 2019-02-07
US20220378852A1 (en) 2022-12-01
CN116570628A (zh) 2023-08-11
BR112015024621A8 (pt) 2019-12-10
JP2020152734A (ja) 2020-09-24
WO2014160950A1 (en) 2014-10-02
UA120036C2 (uk) 2019-09-25
ES2922378T3 (es) 2022-09-14
US11439669B2 (en) 2022-09-13
RU2718670C2 (ru) 2020-04-13
BR112015024621A2 (pt) 2017-07-18
ES2815564T3 (es) 2021-03-30
EP4108248A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
SG10201902765VA (en) C. novyi for the treatment of solid tumors in humans
SG10201902664RA (en) Combination therapy for treating cancer
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
WO2016025635A3 (en) Combination therapy for treating cancer
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
PH12016502354A1 (en) Pharmaceutical composition
MX375442B (es) Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MY186977A (en) Tetrasubstituted alkene compounds and their use
NZ729643A (en) Combination therapy for treating cancer
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
SG10201909199PA (en) Method for treating cancer
WO2016043874A3 (en) Combination therapy for treating cancer
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
PH12020500666A1 (en) Pladienolide compounds and their use
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
GB2553439A (en) Methods for scoring chromosomal instabilities
WO2014160967A3 (en) C. novyi for the treatment of solid tumors in non-human animals
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
EA202193276A1 (ru) Способы лечения холангиокарциномы

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2022 BY CPA GLOBAL

Effective date: 20210211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2023 BY CPA GLOBAL

Effective date: 20220210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2024 BY CPA GLOBAL

Effective date: 20230210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2025 BY AJ PARK

Effective date: 20240325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2026 BY AJ PARK

Effective date: 20250218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2027 BY AJ PARK

Effective date: 20260225